Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, ...

Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the ...

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...

People with type 2 diabetes who used semaglutide (Ozempic) versus other drugs had a lower risk of Alzheimer's disease and related dementia, especially vascular dementia, electronic health records ...

US biotech Capricor Therapeutics (Nasdaq: CAPR) saw its shares leap more than 31% to $7.82 by mid-morning on positive development for its deramiocel. Capricor said that, following recent meetings with ...

Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path ...

Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the ...